Palleon Pharmaceuticals Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 42

Employees
  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $100M

  • Investors
  • 8

Palleon Pharmaceuticals General Information

Description

Developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer. The company's biotechnology platform integrates technologies and insights from scientific leaders all over the world in the fields of glycoscience and human immunology to create a novel approach to treat cancer by targeting multiple immune cell types, providing physicians with a wider range of rational combination therapies to treat cancer and tackle resistance to first-generation immuno-oncology agents.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 266 2nd Avenue
  • Waltham, MA 02451
  • United States
+1 (857) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Palleon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 16-Sep-2020 $100M 00000 00000 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 04-Oct-2017 000.00 000.00 000.00 Completed Clinical Trials - Phase 1
1. Accelerator/Incubator Completed Clinical Trials - Phase 1
To view Palleon Pharmaceuticals’s complete valuation and funding history, request access »

Palleon Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
Series A 00,000,000 00.000000 00.00 00 00 00 00 00.000
To view Palleon Pharmaceuticals’s complete cap table history, request access »

Palleon Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer. The company's
Drug Discovery
Waltham, MA
42 As of 2022
00000
0000 0000-00-00
00000000000 00000

000000

voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000

000000

oris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate ve
0000 000000000
San Diego, CA
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Palleon Pharmaceuticals Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000000 00000000 Formerly VC-backed San Diego, CA 000 00000 000000000 00000
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
000000000 Venture Capital-Backed Berlin, Germany 00 00000 0000000000 0 00000
0000000 Venture Capital-Backed Berlin, Germany 0 00.000 000000000 00.000
You’re viewing 5 of 14 competitors. Get the full list »

Palleon Pharmaceuticals Patents

Palleon Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020298628-A1 Sialidase-cd20-antibody fusion proteins and methods of use thereof Pending 03-Jul-2019 00000000000
CA-3145672-A1 Sialidase-cd20-antibody fusion proteins and methods of use thereof Pending 03-Jul-2019 00000000000
EP-3994179-A1 Sialidase-cd20-antibody fusion proteins and methods of use thereof Pending 03-Jul-2019 00000000000
AU-2020300680-A1 Recombinant sialidases and methods of using the same Pending 03-Jul-2019 00000000000
CA-3145772-A1 Recombinant sialidases and methods of using the same Pending 03-Jul-2019 A61K47/6815
To view Palleon Pharmaceuticals’s complete patent history, request access »

Palleon Pharmaceuticals Executive Team (7)

Name Title Board Seat Contact Info
James Broderick MD Co-Founder, Chief Executive Officer, President & Board Member
Li Peng Ph.D Chief Scientific Officer
John Hennessy Vice President, Operations & Finance
Paul Crocker Ph.D Scientific Advisors
David Feltquate Ph.D Co-Chief Medical Officer
You’re viewing 5 of 7 executive team members. Get the full list »

Palleon Pharmaceuticals Board Members (19)

Name Representing Role Since
Alan Colowick MD Matrix Capital Management Board Member 000 0000
David Johnson Self Board Member 000 0000
Deepa Pakianathan Ph.D Palleon Pharmaceuticals Board Member 000 0000
Denis Patrick Ph.D Self Board Member 000 0000
James Broderick MD Palleon Pharmaceuticals Co-Founder, Chief Executive Officer, President & Board Member 000 0000
You’re viewing 5 of 19 board members. Get the full list »

Palleon Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Palleon Pharmaceuticals Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Citadel Enterprise Americas Hedge Fund Minority 000 0000 000000 0
Matrix Capital Management Hedge Fund Minority 000 0000 000000 0
Surveyor Capital Hedge Fund Minority 000 0000 000000 0
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Pfizer Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »